COYA
Coya Therapeutics, Inc.
$4.74
+2.16%
$111.2M
No data for this timeframe.
Vol
Market Cap$111.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders24 funds
Inst. Value$10.6M
Inst. Activity4 buys / 1 sells
SEC Reports4
Recent Activity
May 12, 2026
SEC
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners LLC, allowing the com
8-K — Impact 4/10
May 7, 2026
earnings_calendar
COYA Q1 2026 Earnings Scheduled — 2026-05-07
Apr 9, 2026
Insider
Pavao Mark H was granted 10,000 shares
Director
Apr 2, 2026
SEC
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as part of a planned le
8-K — Impact 3/10
Mar 23, 2026
SEC
Coya Therapeutics, Inc. has had a Form S-3 shelf registration become effective, allowing the company to issue unspecifie
EFFECT — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
103,964 shares ($409.6K)
Inst.
DIMENSIONAL FUND ADVISORS LP — DOUBLED
95,919 shares ($377.3K)
Price Targets
$15.21
+221.0% upside
Strong Buy
Current $4.74
Low $12.00
Median $15.50
High $18.00
7 analysts
$12.00
$18.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 12, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jun 5, 2026 | Roth Capital | INITIATE | Buy |
| Apr 10, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▲ +3.3% | $-0.37 — $-0.36 | -1% YoY | 4 |
| Next Q | $-0.39 ▼ -2.6% | $-0.41 — $-0.37 | -200% YoY | 4 |
| Current FY | $-1.48 ▲ +1.5% | $-1.52 — $-1.42 | -16% YoY | 4 |
| Next FY | $-1.83 ▼ -58.2% | $-2.03 — $-1.66 | -24% YoY | 3 |
Latest Reports
NEUTRAL
8-K
4/10
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners LLC, allowing the com
May 12, 2026
NEUTRAL
8-K
3/10
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as part of a planned le
Apr 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.3M | — |
| Alyeska Investment Group, L.P. | $3.2M | — |
| MARSHALL WACE, LLP | $889.6K | DOUBLED |
| VANGUARD FIDUCIARY TRUST CO | $551.2K | — |
| RENAISSANCE TECHNOLOGIES LLC | $409.6K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 9, 2026 | Pavao Mark | A | $0.00 |
24 institutional holders with $10.6M total value (2,711,188 shares) as of 2026-Q1. Top holders: VANGUARD, Alyeska, MARSHALL. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 844,913 | $3.3M | 31.3% | — |
| 2 | Alyeska Investment Group, L.P. | 800,000 | $3.2M | 29.7% | — |
| 3 | MARSHALL WACE, LLP | 225,792 | $889.6K | 8.4% | DOUBLED +438.8% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 139,886 | $551.2K | 5.2% | — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 103,964 | $409.6K | 3.9% | ADD +55.4% |
| 6 | DIMENSIONAL FUND ADVISORS LP | 95,919 | $377.3K | 3.5% | DOUBLED +205.2% |
| 7 | MORGAN STANLEY | 85,700 | $337.7K | 3.2% | ADD +60.6% |
| 8 | BlackRock, Inc. | 82,769 | $326.1K | 3.1% | — |
| 9 | STATE STREET CORP | 79,813 | $314.5K | 3.0% | ADD +44.5% |
| 10 | JONES FINANCIAL COMPANIES LLLP | 44,960 | $178.0K | 1.7% | — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 39,316 | $154.9K | 1.5% | — |
| 12 | Point72 Asset Management, L.P. | 37,681 | $148.5K | 1.4% | TRIM -38.8% |
| 13 | CIBC Bancorp USA Inc. | 25,000 | $98.5K | 0.9% | — |
| 14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 20,626 | $81.3K | 0.8% | — |
| 15 | CITADEL ADVISORS LLC | 16,859 | $66.4K | 0.6% | ADD +51.3% |
| 16 | ROYAL BANK OF CANADA | 13,392 | $53.0K | 0.5% | TRIM -35.2% |
| 17 | RAYMOND JAMES FINANCIAL INC | 11,673 | $46.0K | 0.4% | — |
| 18 | HighTower Advisors, LLC | 10,029 | $39.5K | 0.4% | — |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 10,000 | $39.4K | 0.4% | — |
| 20 | Vanguard Global Advisers, LLC | 5,879 | $23.2K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 66,900 | 103,964 | +55.4% | $409.6K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 31,429 | 95,919 | +205.2% | $377.3K | 2026-Q1 |
| MORGAN STANLEY | ADD | 53,356 | 85,700 | +60.6% | $337.7K | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 61,584 | 37,681 | -38.8% | $148.5K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 1,500 | 2,000 | +33.3% | $7.9K | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 41,825 | 225,358 | +438.8% | $1.3M | 2025-Q4 |
| STATE STREET CORP | ADD | 48,100 | 69,510 | +44.5% | $403.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 34,800 | 66,900 | +92.2% | $388.0K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,525 | 53,356 | +3398.8% | $309.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 215 | 39,784 | +18404.2% | $230.7K | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 19,781 | 31,429 | +58.9% | $182.3K | 2025-Q4 |
| Rockefeller Capital Management L.P. | DOUBLED | 500 | 1,500 | +200.0% | $8.7K | 2025-Q4 |
| CITADEL ADVISORS LLC | ADD | 43,120 | 65,240 | +51.3% | $371.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,000 | 34,800 | +148.6% | $198.4K | 2025-Q3 |
| MORGAN STANLEY | ADD | 800 | 1,525 | +90.6% | $8.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 142 | 215 | +51.4% | $1.2K | 2025-Q3 |
| UBS Group AG | TRIM | 34,089 | 15,127 | -55.6% | $87.0K | 2025-Q2 |
| ROYAL BANK OF CANADA | TRIM | 20,652 | 13,383 | -35.2% | $77.0K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 2,800 | 6,740 | +140.7% | $43.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 800 | 2,800 | +250.0% | $16.0K | 2024-Q4 |
| ROYAL BANK OF CANADA | TRIM | 33,698 | 22,902 | -32.0% | $148.0K | 2024-Q3 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 9, 2026 | Pavao Mark H | Director | AWARD | 10,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
4/10
Coya Therapeutics entered into an at-the-market (ATM) equity sales agreement with Leerink Partners L
May 12, 2026
NEUTRAL
8-K
3/10
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as
Apr 2, 2026
NEUTRAL
EFFECT
4/10
Coya Therapeutics, Inc. has had a Form S-3 shelf registration become effective, allowing the company
Mar 23, 2026
NEUTRAL
S-3
3/10
Coya Therapeutics filed an S-3 shelf registration to register 2,522,727 shares of common stock for r
Mar 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.21 mean target
+221.0% upside
Strong Buy (1.00)
$12.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $4.74 |
| Target Low | $12.00 |
| Target Mean | $15.21 |
| Target Median | $15.50 |
| Target High | $18.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.37 | $-0.36 | -0.7% | +3.3% | 1↑ 1↓ | $0.0B | -36.3% | 4 |
| Next Q 2026-09-30 |
$-0.39 | $-0.41 | $-0.37 | -200.0% | -2.6% | 1↑ 1↓ | $0.0B | -97.8% | 4 |
| Current FY 2026-12-31 |
$-1.48 | $-1.52 | $-1.42 | -16.1% | +1.5% | 1↑ 1↓ | $0.0B | -70.4% | 4 |
| Next FY 2027-12-31 |
$-1.83 | $-2.03 | $-1.66 | -23.8% | -58.2% | 1↑ 0↓ | $0.0B | 111.3% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.362 | |
| 7d ago | $-0.362 | |
| 30d ago | $-0.375 | +0.013 |
| 60d ago | $-0.383 | +0.021 |
| 90d ago | $-0.370 | +0.008 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jun 5, 2026 | Roth Capital | INITIATE | — | Buy |
| Apr 10, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
COYA Q1 2026 Earnings Scheduled — 2026-05-07
Mar 24, 2026
earnings_calendar
COYA Q4 2025 Earnings Before Market Open — 2026-03-24